

Information about proposed Board of Directors Annual General Meeting 2013

Proposal for re-election of the current members of the board of directors:

Adine Grate Axén

Born 1961.

Board member since 2010.

M.Sc. from Stockholm School of Economics, Harvard AMP.

Other appointments: Chairman of Nasdaq OMX Stockholm's Listing Committee and Alhanko & Johnson AB. Vice Chairman of Sjunde AP-fonden. Advisor and working Board member of HI3GS Holding AB. Board member of Sampo OY, 3G Infrastructure Services AB, HI3G Denmark ApS and Swedavia AB.

Previous appointments: Member of the Commission for the sale of shares in companies with state ownership. Board member of Gambro AB, OMX AB 1994–2007, various senior management positions and Board assignments within Investor AB and member of the management group 1999–2007. Board member of Acne Studios Holding AB, EDB Ergo Group AS and Carnegie Investment Bank AB.

Shares: 32,000

Independent in relation to the company and its management and in relation to the company's principal shareholders.

Matthew Gantz

Born 1965.

Board member since 2012.

BA Princeton University and MBA from Harvard Business School.

Other appointments: US Executive Vice President of BTG, an international specialist healthcare company.

Previous appointments: Founder and previously CEO of Acureon Pharmaceuticals, President and CEO of Hydrabiosciences Inc., Vice President Europe for Chiron's Biopharmaceutical Division and General Manager for PathoGenesis Europe. Prior to Chiron/PathoGenesis, a variety of US sales and marketing roles at Abbott Laboratories Diagnostic Division.

Shares: 0

Independent in relation to the company and its management and in relation to the company's principal shareholders.

Bo Jesper Hansen

Born 1958.

Chairman and Board member since 2010.

M.D. with a Ph.D. from Copenhagen University.

Other appointments: Board member of Hyperion Therapeutics Inc., GenSpera Inc., Topotarget A/S, MipSalus ApS, Zymenex A/S, Orphazyme ApS, Reaplix ApS and CMC Kontrast AB

Previous appointments: Various positions in Swedish Orphan International AB since 1993 including CEO from 1998–2010. Medical advisor for Synthélabo, Pfizer, Pharmacia and Yamanouchi. Founder of Scandinavian Medical Research.

Shares: 8,893,846

Dependent in relation to the company and its management but independent in relation to the company's principal shareholders.

Lennart Johansson

Born 1955.

Board member since 2010.

MBA from Stockholm School of Economics.

Other appointments: Member of the management team and Head of Financial Investments at Investor AB. Board member of Hi3G and Lindorff group.

Previous appointments: CEO in b-business partners and Emerging Technologies AB. Board member of SAAB AB, IBX Group AB, Gambro Holding AB and Mölnlycke Health Care.

Shares: 20,000

Independent in relation to the company and its management but dependent in relation to the company's principal shareholders.

Helena Saxon

Born 1970.

Board member since 2011.

MBA from Stockholm School of Economics.

Other appointments: Investment Manager at Investor AB, Board member of Aleris, Gambro and Mölnlycke Health Care.

Previous appointments: CFO of Hallvarsson & Halvarsson, Vice President of Investor AB and financial analyst at Goldman Sachs.

Shares: 15,500

Independent in relation to the company and its management but dependent in relation to the company's principal shareholders.

Hans GCP Schikan

Born 1958.

Board member since 2011.

Pharm.D, Utrecht University.

Other appointments: CEO of Prosensa, The Netherlands. Board member of Top Institute Pharma. Member of the Advisory Board of BioScience Park Leiden. Member of Core Team Dutch Top Sector Life Sciences & Health.

Previous appointments: Chairman of Dutch Association of the Innovative Pharmaceutical Industry, Nefarma. Various senior management positions within previous Organon and Genzyme.

Shares: 0

Independent in relation to the company and its management and in relation to the company's principal shareholders.

Hans Wigzell

Born 1938.

Board member since 2005.

M.D,D.Sc., Professor of Immunology.

Other appointments: Chairman of Karolinska Development AB and Rhenman & Partners Asset Management AB. Board member of RaySearch Laboratories AB (publ), Intercell AG (publ), Sarepta Therapeutics Inc and AB Wigzell produktion. Member of the Royal Swedish Academy of Sciences and the Royal Swedish Academy of Engineering Sciences.

Previous appointments: President of Karolinska Institutet. Board member of NeoDynamics AB, PROBI AB and Diamyd Medical AB.

Shares: 200,000

Independent in relation to the company and its management and in relation to the company's principal shareholders.